Pivotal bioVenture Partners is a San Francisco-based venture capital firm that focuses on investing in early-stage biotechnology companies in North America and Europe. Established in 2017, the firm targets innovative therapeutic products and platforms aimed at addressing significant unmet medical needs. Pivotal bioVenture Partners invests at various stages of a company's development, from inception through mid and late-stage clinical development. The firm's team possesses a diverse range of expertise in venture capital, company building, and drug discovery, enabling them to effectively collaborate with entrepreneurs to advance their business objectives.
SanReno Therapeutics develop, manufacture and commercialize kidney disease therapies in the People’s Republic of China, Hong Kong, Macau, Taiwan and Singapore (the “Territory”). SanReno Therapeutics formed with JV of Chinook Therapeutics and Frazier Healthcare Partners and Pivotal bioVenture Partners China.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.